| News & Announcements | 10/01/2024 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products | | | | | | 10/1/2024 | | | |
| Updated Policies | Sacral Nerve Stimulation (SNS) and Posterior Tibial Nerve Stimulation (PTNS) for the Control of Incontinence | 11.17.04y | | 10/1/2024 | | | 10/1/2024 | Medical Necessity Criteria;Medical Coding | | |
| Reissue Policies | Procedures for the Treatment of Gastroesophageal Reflux Disease (GERD) | 11.03.11q | | 1/2/2023 | 10/2/2024 | | 10/2/2024 | | | |
| Reissue Policies | Interleukin-5 (IL-5) Antagonist (e.g., Cinqair®) | 08.01.23i | | 10/4/2021 | 10/2/2024 | | 10/2/2024 | | | |
| Reissue Policies | Loncastuximab tesirine-lpyl (Zynlonta®) | 08.00.59c | | 10/23/2023 | 10/2/2024 | | 10/2/2024 | | | |
| Reissue Policies | Chemical Peels | 11.08.08h | | 12/26/2022 | 10/2/2024 | | 10/2/2024 | | | |
| Reissue Policies | Procedures for the Treatment of Acne | 11.08.29e | | 10/1/2016 | 10/2/2024 | | 10/2/2024 | | | |
| Reissue Policies | Selective Photothermolysis Using Pulsed-Dye Lasers (PDL) | 11.08.04i | | 7/11/2022 | 10/2/2024 | | 10/2/2024 | | | |
| Coding Update | Ultraviolet Light Therapy for the Treatment of Dermatological Conditions | 07.07.02o | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Treatment of Medical and Surgical Complications | 11.00.02i | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Vagus Nerve Stimulation (VNS) | 11.15.16v | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Brentuximab Vedotin (Adcetris®) | 08.01.13j | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Prescription Digital Therapeutics and Mobile-Based Health Management Applications | 12.00.05c | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Ambulatory Blood Pressure Monitoring (ABPM) and Home Blood Pressure Monitoring (HBPM) Devices | 07.02.09j | | 10/1/2024 | 10/1/2024 | | 10/1/2024 | | | |
| Coding Update | Hair Transplants and Cranial Prostheses (Wigs) | 11.08.01h | | 10/1/2024 | 10/1/2024 | | 10/1/2024 | | | |
| Coding Update | Home Prothrombin Time Monitoring | 05.00.26l | | 10/1/2024 | 10/1/2024 | | 10/1/2024 | | | |
| Coding Update | Knee Orthoses | 05.00.47t | | 10/1/2024 | 10/1/2024 | | 10/1/2024 | | | |
| Coding Update | Transcutaneous Electrical Nerve Stimulators (TENS) and Associated Supplies | 05.00.74j | | 10/1/2024 | 10/1/2024 | | 10/1/2024 | | | |
| Coding Update | Carfilzomib (Kyprolis®) | 08.01.05k | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Equipment, Supplies, and Pharmaceuticals for the Treatment of Diabetes | 05.00.05s | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Esophagogastroduodenoscopy (EGD) and Endoscopic Retrograde Cholangiopancreatography (ERCP) | 07.02.22h | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Home-Based Sleep Studies | 07.03.01d | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Denervation of the Spinal Nerves for Chronic Pain (Independence Administrators) | 11.15.09q | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Anesthesia Services for Epidural, Paravertebral Facet and Sacroiliac Joint Injections for Spinal Joint Management | 01.00.12c | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Transcatheter Cardiac Valve Procedures | 11.02.25j | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Wireless Capsule Endoscopy for Gastrointestinal (GI) Disorders | 07.05.02s | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Nivolumab (Opdivo®) | 08.01.62d | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Epcoritamab-bysp (EPKINLY™) | 08.02.12a | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Dermabrasion for Rhinophyma, Septoplasty, Rhinoplasty, and Septorhinoplasty | 11.16.01l | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Drug-Eluting Beads and Bland Embolization for the Treatment of Hepatic Malignancies | 07.05.07e | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Panniculectomy, Abdominoplasty, Abdominal Lipectomy, and Other Excisions of Redundant Skin | 11.08.06k | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Radioembolization for Primary and Metastatic Tumors of the Liver | 09.00.48h | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Radioimmunotherapy with Ibritumomab Tiuxetan (Zevalin®) (Independence Administrators) | 08.00.08k | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Removal of Breast Implants | 11.08.14o | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Speech and Non-Speech Generating Devices | 05.00.32m | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Transcatheter Arterial Chemoembolization (TACE) of Hepatic Malignancies | 07.05.06h | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Octreotide Acetate (Sandostatin® LAR Depot) | 08.01.10j | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Autonomic Nervous System Testing | 07.03.23g | | 10/1/2024 | 10/1/2024 | | 10/1/2024 | | | |
| Coding Update | Preventive Care Services | 00.06.02as | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Pemetrexed (Pemfexy™) | 08.00.87n | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Teplizumab-mzwv (Tzield) | 08.01.99a | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Treatments for Complex Regional Pain Syndrome (CRPS) | 08.00.57s | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Self-Administered Drugs and Biologics | 08.00.78as | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Omalizumab (Xolair®) | 08.00.55k | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Coverage of Anticancer Prescription Oral and Injectable Drugs and Biologics and Supportive Agents | 08.01.08r | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG) | 08.00.13ai | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Tafasitamab-cxix (Monjuvi®) | 08.01.81d | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Asparaginase Erwinia Chrysanthemi (Erwinaze®), asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze®) | 08.01.35h | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Chimeric Antigen Receptor (CAR) Therapy | 08.01.43n | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Denosumab (Prolia®, Xgeva®), Romosozumab-aqqg (Evenity®) | 08.00.94s | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Glofitamab-gxbm (Columvi) | 08.02.07c | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Use | 08.00.66v | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Lanreotide (Somatuline® Depot) | 08.01.40g | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)/(Abraxane® for Injectable Suspension) | 08.00.90r | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Pembrolizumab (Keytruda®) | 08.01.63e | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI) | 07.13.06n | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Insertion of Implantable Infusion Pumps | 11.15.03o | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Photodynamic Therapy (PDT) Using Verteporfin (Visudyne®) | 07.13.05l | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Wound Care: Skin Substitutes for the Treatment of Burns and Chronic, Non-Healing Wounds | 11.08.20am | | 10/1/2024 | | | 10/1/2024 | | | |
| Coding Update | Modifier 62: Two Surgeons | 00.10.11aa | | 10/1/2024 | | | 10/4/2024 | | | |
| Coding Update | Modifiers for Assistant-at-Surgery Services: 80, 81, 82, and AS | 00.10.18y | | 10/1/2024 | | | 10/4/2024 | | | |
| Coding Update | Modifier 25: Significant, Separately Identifiable Evaluation and Management Service by the Same Physician or Other Qualified Health Care Professional on the Same Day of the Procedure or Other Service | 03.00.06aa | | 10/1/2024 | | | 10/4/2024 | | | |
